Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $154.74 Analyst target: $227.44 Upside: 46.98%
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.